Skip to main content
Home
Issues
2023
June 2023 - Vol 16 No 1
2022
December - Vol 15 No 4
September - Vol 15 No 3
June - Vol 15 No 2
March - Vol 15 No 1 - Online Only
Issue Archive
Special Issues
December 2023 Vol 16, Payers' Guide to FDA Updates
Supplements
Special Issue Archive
Topics
Conference Correspondent
ESMO 2023 - Small Cell Lung Cancer
Web Exclusives
Web Exclusive Topics
All Web Exclusives
Select Drug Profiles
FDA Approvals
In the News
Press Releases
Videos
Interview with the Innovators
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Board
Editorial Process
Advertising Contacts
Advertising Policy
Reprints
Subscribe
Home
Issues
2023
June 2023 - Vol 16 No 1
2022
December - Vol 15 No 4
September - Vol 15 No 3
June - Vol 15 No 2
March - Vol 15 No 1 - Online Only
Issue Archive
Special Issues
December 2023 Vol 16, Payers' Guide to FDA Updates
Supplements
Special Issue Archive
Topics
Conference Correspondent
ESMO 2023 - Small Cell Lung Cancer
Web Exclusives
Web Exclusive Topics
All Web Exclusives
Select Drug Profiles
FDA Approvals
In the News
Press Releases
Videos
Interview with the Innovators
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Board
Editorial Process
Advertising Contacts
Advertising Policy
Reprints
Conference Correspondent
News, views, and coverage of important topics and discussions from oncology conferences and events.
[widgetkit id="1" name="CC Event Nav"]
Long-Term Efficacy and Safety Results of SIRROUND-D Trial of Sirukumab in Patients with Active RA Despite DMARD Treatment
Read More
Upadacitinib (ABT-494) Is Effective in Patients with Active RA with Inadequate Response to Conventional Synthetic DMARDs
Read More
Sarilumab plus DMARDs Lower HbA1c in Diabetic and Nondiabetic Patients with Rheumatoid Arthritis
Read More
Highly Sensitive Cardiac Troponin I Levels in Peripheral Blood Predict CV Events in Patients with RA
Read More
Cost per Effectively Treated Patient with Sarilumab for Active, Moderate-to-Severe RA
Read More
Sarilumab Efficacy Maintained or Improved in Patients with RA Who Previously Received Sarilumab or Tocilizumab
Read More
Sustained Response in TARGET Study of Sarilumab + csDMARDs versus Placebo in RA Patients with Inadequate Response to TNF Inhibitors
Read More
Sarilumab + csDMARDs Effective Regardless of Baseline Disease Activity in RA Patients with Inadequate Response to TNF Inhibitors
Read More
Tocilizumab Monotherapy as Effective as TNF Inhibitors plus MTX in Patients with RA
Read More
An Updated Integrated Safety Analysis of Baricitinib for the Treatment of Moderate-to-Severe RA
Read More
10
11
12
13
14
15
16
Page 13 of 25
Results 121 - 130 of 242